biote Corp. Subsidiary Initiates Voluntary Recall of Hormone Pellets
BTMD is trading near its 52-week low of $2.09 (3.3% above the low).
Summary
biote Corp.'s subsidiary, Asteria Health, initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter, expecting a $1.3 million Q4 charge and an additional $1.0 million in 2026.
Key Events · Legal and Risk Events · BTMD
-
Voluntary Product Recall Initiated
F.H. Investments, Inc. (Asteria Health), a wholly-owned subsidiary of biote Corp., initiated a voluntary recall of specific lots of hormone pellets due to the potential presence of metal particulate matter.
-
FDA Notified
The recall, affecting products shipped between May 20, 2025, and January 19, 2026, is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).
-
Estimated Financial Impact
The company expects a one-time charge of approximately $1.3 million in Q4 2025 for inventory write-off and an additional $1.0 million in 2026 for recall-related costs.
-
No Anticipated Material Operational Impact
biote Corp. does not believe the recall will materially impact its ability to provide pellets to practitioner partners or their ability to service patients.
Analysis · BTMD · Life Sciences
The voluntary recall by biote Corp.'s subsidiary, Asteria Health, due to potential metal particulate matter in hormone pellets, represents a notable financial and operational risk. While the company expects a one-time charge of $1.3 million in Q4 2025 for inventory write-off and an additional $1.0 million in 2026 for recall-related costs, the total estimated impact of $2.3 million is significant. The involvement of the FDA and the nature of the product (bioidentical hormones) elevate the seriousness of the event. Although management states they do not anticipate a material impact on their ability to supply practitioners, investors will closely monitor future disclosures for any unforeseen operational disruptions or reputational damage, especially given the stock is trading near its 52-week low.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.7% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BTMD was trading at $2.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.6M. The 52-week trading range was $2.09 to $5.93. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.